ContractProduct Rights Agreement • May 18th, 2023 • Alimera Sciences Inc • Pharmaceutical preparations • Georgia
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • May 18th, 2023 • Alimera Sciences Inc • Pharmaceutical preparations
This COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of May 17, 2023 (the “Effective Date”), by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 480 Pleasant Street, Suite C-400, Watertown, MA 02472 (“EyePoint”), and Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005 (“Alimera”) (collectively, the “Parties” and each, a “Party”). Capitalized terms used, but not otherwise defined, in this Agreement have the meanings assigned to them in the Product Rights Agreement (as defined below).
JOINDER AND AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 18th, 2023 • Alimera Sciences Inc • Pharmaceutical preparations • Delaware
This Joinder and Amendment to Securities Purchase Agreement (this “Amendment”) dated as of May 17, 2023 (the “Amendment Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, amends that certain Securities Purchase Agreement (the “Purchase Agreement”) dated as of March 24, 2023, between the Company and the purchasers party thereto (the “Original Purchasers”).
